Patents Assigned to Pfizer
  • Chemical compounds
    Patent number: 9067922
    Abstract: The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: June 30, 2015
    Assignee: Pfizer Limited
    Inventors: Robert Ian Storer, Nigel Alan Swain, Robert McKenzie Owen
  • Prostate-associated antigens and vaccine-based immunotherapy regimens
    Patent number: 9066898
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: June 30, 2015
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20150175573
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g.
    Type: Application
    Filed: March 4, 2015
    Publication date: June 25, 2015
    Applicant: PFIZER INC.
    Inventors: MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, MICHAEL ERIC GREEN, JACLYN LOUISE HENDERSON, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, LEI ZHANG
  • ARYL AND HETEROARYL FUSED LACTAMS
    Publication number: 20150175572
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: March 9, 2015
    Publication date: June 25, 2015
    Applicant: PFIZER INC.
    Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, Indrawan James MCALPINE, Sacha NINKOVIC, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES, Luke Raymond ZEHNDER
  • SITE-SPECIFIC INTEGRATION
    Publication number: 20150167020
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e.g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Application
    Filed: June 20, 2013
    Publication date: June 18, 2015
    Applicants: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Device for dispensing a plurality of unitary doses of dry powder, and inhaler comprising such device
    Patent number: 9056175
    Abstract: Device for dispensing a plurality of unitary doses (2) of dry powder, includes at least one support comprising conduits each defining a flow path for an airstream carrying one of the unitary dose (2), the support having first (26) and second (27) members secured to one another so that a first conduit portion (29) of the first member faces a second conduit portions (43) of the second member to define one of the conduits, and a first separation portion (30) of the first member faces a second separation portions (45) of the second member, the support comprising a plurality of barrier-forming elements (31, 46) each arranged between corresponding first (30) and second (45) separation portions to prevent dry powder from passing from one of the conduits to one of the adjacent conduits.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: June 16, 2015
    Assignee: PFIZER LIMITED
    Inventors: Nicholas John Bowman, Declan Reilly
  • Pyridine-2-derivatives as smoothened receptor modulators
    Patent number: 9056865
    Abstract: The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R1, R2, R3, R4, R5, R5b, R6, R7, R8, R9, R10, R11, R20, R21, R22 and R23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: June 16, 2015
    Assignee: Pfizer Inc.
    Inventors: Sajiv Krishnan Nair, Simon Paul Planken
  • Process for forming amorphous atorvastatin
    Patent number: 9056831
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: February 8, 2014
    Date of Patent: June 16, 2015
    Assignee: Pfizer Inc.
    Inventors: Antone John deBettencourt, III, Peter Robert Rose, Evgenyi Shalaev, George Joseph Quallich, Carl Bernard Ziegler
  • Glucagon receptor modulators
    Patent number: 9056834
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 16, 2015
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS
    Publication number: 20150159134
    Abstract: The invention relates to a method for producing retinal pigment epithelial cells.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 11, 2015
    Applicant: PFIZER LIMITED
    Inventors: PARUL CHOUDHARY, BEATA SURMACZ-CORDLE, HEATHER DAWN ELLEN FOX, PAUL JOHN WHITING
  • Beneficial effects of combination therapy on cholesterol
    Patent number: 9050342
    Abstract: The present invention discloses pharmaceutical combination therapies for the treatment or prevention of diseases in a mammal comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the same and kits for achieving a therapeutic effect in a mammal comprising pharmaceutical combination therapies are further described.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: June 9, 2015
    Assignee: Pfizer Inc.
    Inventors: Keith Stuart Kanik, Samuel H. Zwillich, Mary Gardiner Boy
  • N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20150152109
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 4, 2015
    Applicant: PFIZER INC.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith
  • Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    Patent number: 9045499
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: June 2, 2015
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Elizabeth Mary Beck, Jennifer Elizabeth Davoren, Erik Alphie LaChapelle, Brian Thomas O'Neill
  • Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
    Patent number: 9045487
    Abstract: The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: June 2, 2015
    Assignee: PFIZER INC.
    Inventors: Patricia Ann Basford, Anthony Michael Campeta, Adam Gillmore, Matthew Cameron Jones, Eleftherios Kougoulos, Suman Luthra, Robert Walton
  • Hexahydropyrano[3,4-][1,3]thiazin-2-amine compounds
    Patent number: 9045498
    Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: June 2, 2015
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Jennifer Elizabeth Davoren, Brian Thomas O'Neill
  • Aryl and heteroaryl fused lactams
    Patent number: 9040515
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 26, 2015
    Assignee: Pfizer Inc.
    Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James McAlpine, Sacha Ninkovic, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes, Luke Raymond Zehnder
  • Pyrrolopyrimidine and purine derivatives
    Patent number: 9040547
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 26, 2015
    Assignee: PFIZER INC.
    Inventors: Hengmiao Cheng, Theodore Otto Johnson, Jr., John Charles Kath, Kevin Kun-Chin Liu, Elizabeth Ann Lunney, Asako Nagata, Sajiv Krishnan Nair, Simon Paul Planken, Scott Channing Sutton
  • PURINE DERIVATIVES
    Publication number: 20150141402
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Applicant: PFIZER INC.
    Inventors: Douglas Carl Behenna, Hengmiao Cheng, Sujin Cho-Schultz, Theodore Otto Johnson, JR., John Charles Kath, Asako Nagata, Sajiv Krishnan Nair, Simon Paul Planken
  • Pyrrolo[2,3-D]pyrimidine derivatives
    Patent number: 9035074
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: May 19, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Process for annealing amorphous atorvastatin
    Patent number: 9034913
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: May 19, 2015
    Assignee: Pfizer Inc.
    Inventors: Renuka D. Reddy, Evgenyi Shalaev, Ravi M. Shanker, Carl B. Ziegler